SEC Form 4 · accession 0001562180-17-001430
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Duane Nash
Director
Period of report
Apr 3, 2017
Accepted (ET)
Apr 4, 2017 · 4:01 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Apr 3, 2017 | S | 991 | $9.2021 | D | 24,677 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award.
- F2The price reported is a weighted average price. This transaction was executed in multiple trades at prices ranging from $9.19 to $9.21, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.